ArticleCancer prevention research (Philadelphia, Pa.)2010
Identification of genes correlated with early-stage bladder cancer progression.
Article in Cancer prevention research (Philadelphia, Pa.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.Cancer prevention research (Philadelphia, Pa.) · 2011Trial
- The clinical value of the EpCAM biomarker and its association with immune cell infiltration in bladder cancer.Diagnostic pathology · 2025Article
- The Expression Regulation and Cancer-Promoting Roles of RACGAP1.Biomolecules · 2024Review
- RACGAP1 promotes lung cancer cell proliferation through the PI3K/AKT signaling pathway.Scientific reports · 2024Article
- Article
- Article
- Rac GTPase activating protein 1 promotes oncogenic progression of epithelial ovarian cancer.Cancer science · 2018Article
- Understanding the biology of urothelial cancer metastasis.Asian journal of urology · 2016Review
- The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer.OncoTargets and therapy · 2016Article
- Modelling bladder cancer in mice: opportunities and challenges.Nature reviews. Cancer · 2015Review
- Cross-contamination of a UROtsa stock with T24 cells--molecular comparison of different cell lines and stocks.PloS one · 2013Article
- Identification of genetic risk associated with prostate cancer using ancestry informative markers.Prostate cancer and prostatic diseases · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Transitional cell carcinoma (TCC) of the bladder ranks fourth in incidence of all cancers in the developed world, yet the mechanisms of its origin and progression remain poorly understood. There are also few useful diagnostic or prognostic biomarkers for this disease. We have combined a transgenic mouse model for invasive bladder cancer (UPII-SV40Tag mice) with DNA microarray technology to determine molecular mechanisms involved in early TCC development and to identify new biomarkers for detection, diagnosis, and prognosis of TCC. We have identified genes that are differentially expressed between the bladders of UPII-SV40Tag mice and their age-matched wild-type littermates at 3, 6, 20, and 30 weeks of age. These are ages that correspond to premalignant, carcinoma in situ, and early-stage and later stage invasive TCC, respectively. Our preliminary analysis of the microarray data sets has revealed approximately 1,900 unique genes differentially expressed (> or =3-fold difference at one or more time points) between wild-type and UPII-SV40Tag urothelium during the time course of tumor development. Among these, there were a high proportion of cell cycle regulatory genes and a proliferation signaling genes that are more strongly expressed in the UPII-SV40Tag bladder urothelium. We show that several of the genes upregulated in UPII-SV40Tag urothelium, including RacGAP1, PCNA, and Hmmr, are expressed at high levels in superficial bladder TCC patient samples. These findings provide insight into the earliest events in the development of bladder TCC as well as identify several promising early-stage biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.